FY2025 EPS Estimates for BCRX Decreased by Cantor Fitzgerald

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) - Analysts at Cantor Fitzgerald reduced their FY2025 earnings estimates for shares of BioCryst Pharmaceuticals in a research report issued to clients and investors on Monday, June 30th. Cantor Fitzgerald analyst S. Seedhouse now anticipates that the biotechnology company will post earnings of $0.06 per share for the year, down from their previous estimate of $0.09. Cantor Fitzgerald has a "Overweight" rating and a $20.00 price target on the stock. The consensus estimate for BioCryst Pharmaceuticals' current full-year earnings is ($0.36) per share. Cantor Fitzgerald also issued estimates for BioCryst Pharmaceuticals' FY2026 earnings at $0.27 EPS.

A number of other analysts have also issued reports on BCRX. Needham & Company LLC reiterated a "buy" rating and set a $17.00 price target on shares of BioCryst Pharmaceuticals in a research note on Wednesday, June 25th. JPMorgan Chase & Co. boosted their price target on shares of BioCryst Pharmaceuticals from $10.00 to $13.00 and gave the stock an "overweight" rating in a research note on Tuesday, May 6th. Wedbush increased their price objective on BioCryst Pharmaceuticals from $16.00 to $18.00 and gave the company an "outperform" rating in a research note on Monday. Barclays lifted their target price on BioCryst Pharmaceuticals from $8.00 to $11.00 and gave the company an "equal weight" rating in a report on Wednesday, May 7th. Finally, Bank of America boosted their target price on BioCryst Pharmaceuticals from $13.00 to $15.00 and gave the stock a "buy" rating in a research note on Tuesday. One investment analyst has rated the stock with a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat, BioCryst Pharmaceuticals has an average rating of "Moderate Buy" and an average target price of $16.70.

BioCryst Pharmaceuticals Price Performance

Shares of BCRX stock traded up $0.02 on Tuesday, hitting $9.02. The stock had a trading volume of 3,551,652 shares, compared to its average volume of 3,032,394. The company's 50 day moving average price is $10.03 and its 200-day moving average price is $8.58. BioCryst Pharmaceuticals has a 1 year low of $6.02 and a 1 year high of $11.31. The firm has a market capitalization of $1.89 billion, a P/E ratio of -34.69, a P/E/G ratio of 2.68 and a beta of 1.04.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in BCRX. Vanguard Group Inc. raised its position in shares of BioCryst Pharmaceuticals by 7.8% during the 4th quarter. Vanguard Group Inc. now owns 21,890,422 shares of the biotechnology company's stock worth $164,616,000 after acquiring an additional 1,583,826 shares in the last quarter. Alkeon Capital Management LLC raised its holdings in BioCryst Pharmaceuticals by 1.7% during the first quarter. Alkeon Capital Management LLC now owns 7,214,021 shares of the biotechnology company's stock worth $54,105,000 after purchasing an additional 120,199 shares in the last quarter. Millennium Management LLC raised its holdings in BioCryst Pharmaceuticals by 382.6% during the first quarter. Millennium Management LLC now owns 3,812,874 shares of the biotechnology company's stock worth $28,597,000 after purchasing an additional 3,022,769 shares in the last quarter. Caligan Partners LP lifted its position in shares of BioCryst Pharmaceuticals by 16.0% during the 4th quarter. Caligan Partners LP now owns 2,995,932 shares of the biotechnology company's stock worth $22,529,000 after buying an additional 412,347 shares during the last quarter. Finally, Two Sigma Advisers LP boosted its holdings in shares of BioCryst Pharmaceuticals by 14.6% in the 4th quarter. Two Sigma Advisers LP now owns 2,499,812 shares of the biotechnology company's stock valued at $18,799,000 after buying an additional 318,800 shares in the last quarter. 85.88% of the stock is owned by institutional investors and hedge funds.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.